Search research articles
Contact Us
Filters
Showing results (431-440 of 551) with videos related to
Page
of 56
Sort By:
JCI Insight
|
September 22, 2022
Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19
Daniel J Schuster, Shelly Karuna, Caroline Brackett, et al.
The Journal of Clinical Investigation
|
September 15, 2022
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
Magdalena E Sobieszczyk, Jill Maaske, Ann R Falsey, et al.
The Journal of Clinical Investigation
|
April 3, 2025
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns
Avy Violari, Kennedy Otwombe, William Hahn, et al.
Clinical and Vaccine Immunology : CVI
|
September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants
Sharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Nature Medicine
|
September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
Holly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Nature Communications
|
August 29, 2024
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Lindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
The Journal of Clinical Investigation
|
April 1, 2024
Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers
Karsten Eichholz, Yoshinori Fukazawa, Christopher W Peterson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 19, 2021
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials
Simbarashe Takuva, Shelly T Karuna, Michal Juraska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 5, 2020
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
Mina C Hosseinipour, Craig Innes, Sarita Naidoo, et al.
Plos One
|
September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
Yunda Huang, Dean Follmann, Martha Nason, et al.
Page
of 56
Search research articles
Search
Showing results (431-440 of 551) with videos related to
Sort By:
Page
of 56
JCI Insight
|
September 22, 2022
Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19
Daniel J Schuster, Shelly Karuna, Caroline Brackett, et al.
The Journal of Clinical Investigation
|
September 15, 2022
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
Magdalena E Sobieszczyk, Jill Maaske, Ann R Falsey, et al.
The Journal of Clinical Investigation
|
April 3, 2025
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns
Avy Violari, Kennedy Otwombe, William Hahn, et al.
Clinical and Vaccine Immunology : CVI
|
September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants
Sharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Nature Medicine
|
September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
Holly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Nature Communications
|
August 29, 2024
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Lindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
The Journal of Clinical Investigation
|
April 1, 2024
Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers
Karsten Eichholz, Yoshinori Fukazawa, Christopher W Peterson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 19, 2021
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials
Simbarashe Takuva, Shelly T Karuna, Michal Juraska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 5, 2020
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
Mina C Hosseinipour, Craig Innes, Sarita Naidoo, et al.
Plos One
|
September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
Yunda Huang, Dean Follmann, Martha Nason, et al.
Page
of 56